Allergy Therapeutics (LSE:AGY) FCF Margin % : -37.65% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Allergy Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was £-12.64 Mil. Allergy Therapeutics's Revenue for the six months ended in Dec. 2023 was £33.57 Mil. Therefore, Allergy Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -37.65%.

As of today, Allergy Therapeutics's current FCF Yield % is -25.94%.

The historical rank and industry rank for Allergy Therapeutics's FCF Margin % or its related term are showing as below:

LSE:AGY' s FCF Margin % Range Over the Past 10 Years
Min: -67.32 Med: 0.29 Max: 12.71
Current: -67.32

During the past 13 years, the highest FCF Margin % of Allergy Therapeutics was 12.71%. The lowest was -67.32%. And the median was 0.29%.

LSE:AGY's FCF Margin % is ranked worse than
86.44% of 1025 companies
in the Drug Manufacturers industry
Industry Median: -0.67 vs LSE:AGY: -67.32

Allergy Therapeutics FCF Margin % Historical Data

The historical data trend for Allergy Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics FCF Margin % Chart

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

3.39

12.71

7.15

-23.44

-56.30

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															5.58	-82.14	-25.90	-117.92	-37.65

Competitive Comparison of Allergy Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's FCF Margin % falls into.

Allergy Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Allergy Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-33.55	/	59.587
	=	-56.30 %

Allergy Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-12.639	/	33.572
	=	-37.65 %

Allergy Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (LSE:AGY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (LSE:AGY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (LSE:AGY) Headlines

No Headlines